Compare Abeona Therapeutics Inc (ABEO) vs American States Water Company (AWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs American States Water Company — how do they compare? Abeona Therapeutics Inc trades at $7.48 (market cap $421.19M), while American States Water Company trades at $87.54 (market cap $3.47B). The key difference: American States Water Company is far larger — about 8.2× Abeona Therapeutics Inc's market cap, and American States Water Company pays a 2.49% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AWR | |
|---|---|---|
Market Cap | $421.19M | $3.47B |
Sector | Health | Utilities |
52-Week High | $7.45 | $89.28 |
52-Week Low | $4.17 | $70.10 |
Enterprise Value | $276.10M | $4.37B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
American States Water (AWR) trades at $87.45, up 1.02% with a bullish technical outlook. The company reported strong Q2 2026 earnings of $1.09 per share, beating estimates, driven by water rate increases and revenue growth of 11.2%. Profitability remains robust with a 20.52% net income margin and ROE of 13.62%. Recent news highlights AWR's 71-year dividend growth streak and inclusion in TIME's America's Best Companies 2026 list.
AWR offers stable income with consistent dividend growth but faces valuation concerns at 23.92 P/E. Analyst consensus is cautious with 50% hold ratings. Key risks include regulatory dependence and competitive pressures. The stock presents a defensive play with reliable dividends but limited near-term upside given current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
